Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Pharmacyclics)"
Count: 113
Selected: 0
NCT IDTitle
NCT03790332Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
NCT03112174Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
NCT02959944Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
NCT02947347Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
NCT02910583Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
NCT02599324A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
NCT02582879informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
NCT02548962Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
NCT02436668Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
NCT02403271A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
NCT02401048A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
NCT02351037Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
NCT02264574A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT02195869Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
NCT02165397Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
NCT02142049Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT02077166Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT01980654Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
NCT01980628Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
NCT01962792Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT01744691A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
NCT01724346Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01722487Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
NCT01578707A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT01478581Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT01325701Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT01292135Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
NCT01236391Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
NCT01217749Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
NCT01149668A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
NCT01109069Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
NCT01105247Safety of PCI-32765 in Chronic Lymphocytic Leukemia
NCT01020006Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
NCT00849654Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
NCT00724984Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
NCT00562224Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
NCT00473577Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
NCT00373204Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
NCT00365183Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
NCT00290004Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00134186Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
NCT00129844Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
NCT00121420Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
NCT00120939Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
NCT00102505A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
NCT00100711Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00096837A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT00086034Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
NCT00080054A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
NCT00080041Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors